Literature DB >> 11030627

p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion.

J E Eid1, A L Kung, R Scully, D M Livingston.   

Abstract

Complexes containing p300, but not CBP, and the nuclear proto-oncoprotein SYT were detected in confluent cultures of G1-arrested cells but not in sparse cells or during S or G2. SYT sequences constitute the N-terminal segment of a fusion oncogene product, SYT-SSX, routinely detected in synovial sarcoma, an aggressive human tumor. SYT/p300 complex formation promotes cell adhesion to a fibronectin matrix, as reflected by compromise of this process in cells expressing SYT dl mutants that retain p300 binding activity and in the primary fibroblasts of p300 but not CBP heterozygous null mice. The mechanism linking the action of SYT/p300 complexes to adhesion function is, at least in part, transcription activation-independent and results in proper activation of beta1 integrin, a major adhesion receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030627     DOI: 10.1016/s0092-8674(00)00072-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  29 in total

1.  Pitx2a expression alters actin-myosin cytoskeleton and migration of HeLa cells through Rho GTPase signaling.

Authors:  Qize Wei; Robert S Adelstein
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

Review 2.  Biological role of p300 in cardiac myocytes.

Authors:  Tetsuhiko Yanazume; Tatsuya Morimoto; Hiromichi Wada; Teruhisa Kawamura; Koji Hasegawa
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

3.  Identification of a novel p300-specific-associating protein, PRS1 (phosphoribosylpyrophosphate synthetase subunit 1).

Authors:  Atsushi Kaida; Yasuo Ariumi; Keiko Baba; Masami Matsubae; Toshifumi Takao; Kunitada Shimotohno
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

4.  The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.

Authors:  Roy Barco; Laura B Hunt; Andrea L Frump; Christina B Garcia; Andrew Benesh; Robert L Caldwell; Josiane E Eid
Journal:  Mol Biol Cell       Date:  2007-08-08       Impact factor: 4.138

5.  Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator.

Authors:  Tamaki Suganuma; Masahiro Kawabata; Tomoko Ohshima; Masa-Aki Ikeda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

6.  Hypoxic adaptation engages the CBP/CREST-induced coactivator complex of Creb-HIF-1α in transactivating murine neuroblastic glucose transporter.

Authors:  Shanthie Thamotharan; Nupur Raychaudhuri; Masatoshi Tomi; Bo-Chul Shin; Sherin U Devaskar
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

Review 7.  Synovial sarcoma: from genetics to genetic-based animal modeling.

Authors:  Malay Haldar; R Lor Randall; Mario R Capecchi
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

8.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].

Authors:  Katayoon H Emami; Cu Nguyen; Hong Ma; Dae Hoon Kim; Kwang Won Jeong; Masakatsu Eguchi; Randall T Moon; Jia-Ling Teo; Se Woong Oh; Hak Yeop Kim; Sung Hwan Moon; Jong Ryul Ha; Michael Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

9.  The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.

Authors:  Roy Barco; Christina B Garcia; Josiane E Eid
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

10.  Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

Authors:  Luisa Cironi; Paolo Provero; Nicola Riggi; Michalina Janiszewska; Domizio Suva; Mario-Luca Suva; Vincent Kindler; Ivan Stamenkovic
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.